Sandoz

Novartis is the only pharmaceutical company with a global leadership position in both patented prescription and generic pharmaceuticals.

Sandoz plays a critical role in the Novartis strategy of offering a range of treatment options to patients, physicians and healthcare providers worldwide. This broad portfolio helps to make affordable, high-quality medicines available to patients around the world and stabilize healthcare systems.

There are two main elements to the Sandoz business strategy:

• Global reach and reputation: In addition to its unique position within Novartis, Sandoz benefits from a strong global presence and powerful brand recognition worldwide.
• Unique expertise: Sandoz differentiates itself primarily through its ability to develop and produce difficult-to-make medicines. Sandoz is the pioneer of biosimilars — follow-on versions of biopharmaceuticals following patent expiry — with the first three approved and marketed products in the EU (human growth hormone Omnitrope, anemia medicine Binocrit / epoetin alfa Hexal, and oncology medicine Zarzio / Filgrastim Hexal).

 

 

Sandoz - adding value all the way up

Sandoz “difficult-to-make” medicines add value by making life easier for patients. The portfolio ranges from complex oral solids through injectables, high-tech patches and state-of-the-art inhalers to biosimilars.

For additional information please roll-over the Sandoz graphic below.

Learn more on the Sandoz website